Show simple item record

dc.contributor.authorOttestad, Anine Larsen
dc.contributor.authorHong, Yan Dai
dc.contributor.authorHalvorsen, Tarje Onsøien
dc.contributor.authorEmdal, Elisabeth Fritzke
dc.contributor.authorWahl, Sissel Gyrid Freim
dc.contributor.authorGrønberg, Bjørn Henning
dc.identifier.citationCancer Treatment and Research Communications. 2021, 29 1-6.en_US
dc.description.abstractIntroduction: Studies have indicated that detection of mutated KRAS or EGFR in circulating tumor DNA (ctDNA) from pre-treatment plasma samples is a negative prognostic factor for non-small cell lung cancer (NSCLC) pa-tients. This study aims to investigate whether this is the case also for NSCLC patients with other tumor mutations. Methods: Tumor tissue DNA from 107 NSCLC patients was sequenced and corresponding pre-treatment plasma samples were analyzed using a limited target next-generation sequencing approach validated in this study. Pa-tients without detected mutations in tumor samples were excluded from further analyses. Results: Mutations were detected in tumor samples from 71 patients. Median age was 68 years, 51% were female, and 88% were current/former smokers, 91% had adenocarcinoma, 4% had squamous cell carcinoma and 6% had other NSCLC. The distribution between stage I, II, III and IV was 33%, 8%, 30%, and 29%, respectively. Between one and three tumor mutation(s) were detected in ctDNA from corresponding plasma samples. Patients with detected ctDNA had shorter PFS (9.6 vs. 41.3 months, HR: 2.9, 95% CI: 1.6–5.2, p =0.0003) and OS (13.6 vs. 115.0 months, HR: 4.0, 95% CI: 2.1–7.6, p =0.00002) than patients without detected ctDNA. ctDNA remained a significant negative prognostic factor for OS (HR: 2.5, 95% CI: 1.1-5.7, p=0.0327), but not PFS, in the multi-variable analyses adjusting for baseline patient and disease characteristics including stage of disease. Conclusions: This study adds further evidence supporting that detectable tumor mutations in cfDNA is associated with a worse prognosis in NSCLC harboring a variety of tumor mutations.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleAssociations between tumor mutations in cfDNA and survival in non-small cell lung canceren_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.source.journalCancer Treatment and Research Communicationsen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal